##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|for the Year Ended 31 Janua
2|023||||||
|---|---|---|---|---|---|---|
||||||2023|2022|
||||Unrestricted|Restricted|Total|Total|
|||Notes|fundf|funds
f|funds
f|fundsf|
|INCOME AND ENDOWMENTS|FROM||||||
|Donations
and legacies|||51|(1)|50||
|Charitable
activities|||||||
|Charitable
activities||||200,798|200,798|187,097|
|Investment
income||3|96,047||96,047|32,799|
|Total|||96,098|200,797|296,895|219,895|
|EXPENDITURE ON|||||||
|Raising funds||4|10,650||10,650|9,029|
|Charitable
activities|||||||
|Charitable
activities|||62485|219663|282148|174259|
|Total|||73,135|219,663|292,798|183,288|
|Net gains/(losses)
on investments|||~)9,736)||~)9736)|9,083|
|NET INCOME/(EXPENDITURE)|||3,227|(18,866)|(15,639)|45,690|
|RECONCILIATION
OF FUNDS|||||||
|Total funds brought
forward|||1,085,987|533,180|1,619,167|1,573,477|
|TOTAL FUNDS CARRIED FORWARD|||1,089,214|514,314|1 603528|1,619,167|
##
|Balance Sheet
||||||
|---|---|---|---|---|---|
|~31 4
2023||||||
|||||2023|2022|
|||Unrestricted|Restricted|Total|Total|
||Notes|fund
f|funds
f|fundsf|fundsf|
|FIXEDASSETS||||||
|Investments|8|215,963||215,963|243,431|
|CURRENT ASSETS||||||
|Debtors|9|541,652|377,541|919,193|756,837|
|Cash at bank||334296|421 954|756 242|818349|
|||1175940|799495|1,675,435|1,575,186|
|CREDITORS||||||
|Amounts
falling due within one year|10|(2,689)|(285,181)|(287,870)|(199,450)|
|NET CURRENT ASSETS||873,251|514,314|1,387,565|1,375,736|
|TOTAL ASSETS LESSCURRENT||||||
|LIABILITIES||1,089,214|514,314|1,603,528|1,619,167|
|NET ASSETS||1,089,214|514,314|1 603528|1 619,167|
|FUNDS||||||
|Unrestricted
funds||||1,089,214|1,085,987|
|Restricted funds||||514,314|533,180|
|TOTAL FUNDS||||1 603528|1,619,167|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|Consolidation|Consolidation|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|In the opinion||ofthe|directors, the||company|and its|subsidiary|undertakings||comprise a small group. The company||||
|has therefore||taken|advantage||of the exemption||provided|by|Section|398 of the|Companies|Act|2006 not to|
|prepare|group|accounts.||||||||||||
|INVESTMENT||INCOME||||||||||||
||||||||||||2023||2022|
||||||||Unrestricted||Restricted||Total||Total|
||||||||funds
6||fundsf||funds||fundsf|
|Diwdend|income||||||96047||||96047||32799|
|RAISING FUNDS||||||||||||||
|Raising|donations||and|legacies||||||||||
||||||||||||2023||2022|
||||||||Unrestricted||Restricted||Total||Total|
||||||||funds||fundsf||funds||fundsf|
|Support|costs||||||||||||6 537|
|Investment
management||||costs||||||||||
||||||||||||2023||2022|
||||||||Unrestricted||Restricted||Total||Total|
||||||||fundsf||fundsf||fundsf||fundsf|
|Support|costs||||||1 721||||1 721||2492|
|Aggregate
amounts|||||||10650||||10650||9029|
##
##
##
##
|2023|2022|
|---|---|
|13|13|
##
||||Unrestricted|Restricted|Total|
|---|---|---|---|---|---|
||||fund|funds|funds|
||||6|6|6|
|INCOME AND ENDOWMENTS||FROM||||
|Donations
and legacies||||||
|Charitable
activities||||||
|Charitable
activities||||187,097|187,097|
|Investment
income|||32799||32 799|
|Total|||32,799|187,096|219,895|
|EXPENDITURE ON||||||
|Raising funds|||9,029||9,029|
|Charitable
activities||||||
|Charitable
activities|||2,652|171,607|174,259|
|Total|||11,681|171,607|183,288|
|Net gains on investments|||9,083||9,083|
|NET INCOME|||30,201|15,489|45,690|
|RECONCILIATION|OF FUNDS|||||
|Total funds
brought|forward||1,055,786|517,691|1,573,477|
|TOTAL FUNDS CARRIED FORWARD|||1085987|533180|1619167|
##
||||Shares|in|in||||
|---|---|---|---|---|---|---|---|---|
||||gl'oup|||Listed|Other||
||||undertakings|||investments
f|investments
f.|Totalsf|
|MARKET VALUE|||||||||
|At 1 February 2022||||||221,061|22,369|243,431|
|Additions||||||25,570||25,570|
|Disposals
Revaluations||||||(33,302)
~17979)|~1757)|(33,302)
~19736)|
|At 31 January 2023||||||195,350|20,612|215,963|
|NET BOOK VALUE|||||||||
|At 31 January 2023||||||195350|20612|215963|
|At 31 January 2022||||||221 061|22 369|243 431|
|There were no investment||assets outside the UK.|||||||
|Cost or valuation|at 31 January 2023 is represented||by:||||||
||||Shares|in|||||
||||group|||I isted|Other||
||||undertakings
f|||investments
f|investmentsf|Totalsf|
|Valuation
in 2023|||||1|195350|20612|215963|
##
##
##
|CREDITORS: AMOU|NTS|F|ALLING DUE WITHIN O|NE YEAR|||
|---|---|---|---|---|---|---|
||||||2023f|2022
f|
|Amounts
owed to group undertakings|||||285,181|197,022|
|Accruals and deferred|income||||2 689|2428|
||||||287 870|199450|
|MOVEMENT
IN FUNDS|||||||
||||||Net||
||||||movement|At|
|||||At 1/2/22|in funds
f|31/1/23
f|
|Unrestricted
funds|||||||
|General
fund||||1,085,987|3,227|1,089,214|
|Restricted funds|||||||
|National
Audit Programmes||||(573)|(75)|(648)|
|NHS Priorities Scheme|||||(13,548)|(13,548)|
|National
Liragutide
&|Exenatide||||||
|Scheme||||22,540||22,540|
|Revise Research Project|||||(228)|(228)|
|Degludec
Nationwide|Audit|||12,516||12,516|
|Nationwide
Audit Therapies|||Audit fund||(42)|(42)|
|Canagliflozin
audit||||44,847|(13,548)|31,299|
|Libre audit||||130,876|25,252|156,128|
|Testosterone
audit||||41,479|53,633|95,112|
|Semaglutide
audit||||284,201|(14,300)|269,901|
|Empagliflozin
audit||||(3,185)|(13,548)|(16,733)|
|ABCD Research fund|||||(72,473)|(72,473)|
|COVID Diabetes
National||Audit||(18,405)|(960)|(19,365)|
|Omnipod
Audit
TOTAL FUNDS||||18,884
533155
1 619.161|30,971
~48866)
~)5639)|49,855
514314
1 683 528|
##
##
|Net movement
in fund|s,
in|cl|ude|d
in the above|are as follows:||||
|---|---|---|---|---|---|---|---|---|
||||||Incoming|Resources|Gains and|Movement|
||||||resourcesf|expendedf|lossesf|in fundsf|
|Unrestricted
funds|||||||||
|General
fund|||||96,098|(73,135)|(19,736)|3,227|
|Restricted funds|||||||||
|National
Audit Programmes||||||(75)||(75)|
|NHS Priorities Scheme||||||(13,548)||(13,548)|
|Revise Research Project||||||(228)||(228)|
|Nationwide
Audit Therapies|||Audit fund|||(42)||(42)|
|Canagliflozin
audit||||||(13,548)||(13,548)|
|Libre audit|||||69,200|(43,948)||25,252|
|Testosterone
audit|||||82,798|(29,165)||53,633|
|Semaglutide
audit|||||(1)|(14,299)||(14,300)|
|Empagliflozin
audit||||||(13,548)||(13,548)|
|ABCD Research fund||||||(72,473)||(72,473)|
|COVID Diabetes
National
Omnipod
Audit
TOTAL FUNDS||Audit|||48 800
200,797
296895|(960)
~17829)
~219,663)
~292798)|~19736)|(960)
~30 971
~18,866)
~15639)|
|Comparatives
for movement||||in funds|||||
||||||||Net||
||||||||movement|At|
|||||||At 1/2/21f|in fundsf|31/1/22
f|
|Unrestricted
funds|||||||||
|General
fund||||||1,055,786|30,201|1,085,987|
|Restricted funds|||||||||
|National
Audit Programmes||||||1,014|(1,587)|(573)|
|National
I iragutide 8|Exenatide||||||||
|Scheme||||||29,489|(6,949)|22,540|
|Degludec
Nationwide|Audit|||||19,465|(6,949)|12,516|
|Canagliflozin
audit||||||51,796|(6,949)|44,847|
|Libre audit||||||122,964|7,912|130,876|
|Testosterone
audit||||||48,428|(6,949)|41,479|
|Semaglutide
audit||||||230,771|53,430|284,201|
|Empagliflozin
audit||||||3,764|(6,949)|(3,185)|
|COVID Diabetes
National||Audit||||10,000|(28,405)|(18,405)|
|Omnipod
Audit|||||||18884|18884|
|||||||517,691|15,489|533,180|
|TOTAL FUNDS||||||1,573,477|45 695|1,619,167|
##
##
|Comparative
net m|ove|men|t|in funds,
included
in th|e above are|as|foll|ows|||
|---|---|---|---|---|---|---|---|---|---|---|
||||||Incoming|||Resources|Gains and|Movement|
||||||resourcesf|||expended
f|losses
f|in fundsf|
|Unrestricted
funds|||||||||||
|General
fund|||||32,799|||(11,681)|9,083|30,201|
|Restricted funds|||||||||||
|National
Audit Programmes
National
Liragutide 8 Exenatide||||||||(1,587)||(1,587)|
|Scheme||||||||(6,949)||(6,949)|
|Degludec
Nationwide||Audit||||||(6,949)||(6,949)|
|Canagliflozin
audit||||||||(6,949)||(6,949)|
|Libre audit|||||65,098|||(57,186)||7,912|
|Testosterone
audit||||||||(6,949)||(6,949)|
|Semaglutide
audit|||||60,998|||(7,568)||53,430|
|Empagliflozin
audit||||||||(6,949)||(6,949)|
|COVID Diabetes
National
Omnipod
Audit|||Audit||61 000||(28,405)
~42 116)|||(28,405)
18884|
||||||187,096||~171,607)|||15,489|
|TOTAL FUNDS|||||219,895||~183288)||9,083|45 690|
|A current year 12 months|||and prior year 12 months||combined|position||is as follows:|||
||||||||||Net||
||||||||||movement|At|
|||||||||At 1/2/21f|in funds
f.|31/1/23|
|Unrestricted
funds|||||||||||
|General
fund||||||||1,055,786|33,428|1,089,214|
|Restricted funds|||||||||||
|National
Audit Programmes||||||||1,014|(1,662)|(648)|
|NHS Pnonties Scheme|||||||||(13,548)|(13,548)|
|National
Liragutide|&|Exenatide|||||||||
|Scheme||||||||29,489|(6,949)|22,540|
|Revise Research Project|||||||||(228)|(228)|
|Degludec
Nationwide||Audit||||||19,465|(6,949)|12,516|
|Nationwide
Audit Therapies||||Audit fund|||||(42)|(42)|
|Canagliflozin
audit||||||||51,796|(20,497)|31,299|
|Libre audit||||||||122,964|33,164|156,128|
|Testosterone
audit||||||||48,428|46,684|95,112|
|Semaglutide
audit||||||||230,771|39,130|269,901|
|Empagliflozin
audit||||||||3,764|(20,497)|(16,733)|
|ABCD Research fund|||||||||(72,473)|(72,473)|
|COVID Diabetes
National|||Audit|||||10,000|(29,365)|(19,365)|
|Omnipod
Audit||||||||49 1155
517691 ~33177||49,855
514314|
|TOTAL FUNDS||||||||I 573.477|30051|1 603 525|
##
|
as follows:||||||,
||
|---|---|---|---|---|---|---|---|
|||||Incoming|Resources|Gains and|Movement|
|||||resources|expendedf|losses|in funds|
|Unrestricted
funds||||||||
|General
fund||||128,897|(84,816)|(10,653)|33,428|
|Restricted funds||||||||
|National
Audit Programmes|||||(1,662)||(1,662)|
|NHS Priorities Scheme|||||(13,548)||(13,548)|
|National
Liragutide
&|Exenatide|||||||
|Scheme|||||(6,949)||(6,949)|
|Revise Research Project|||||(228)||(228)|
|Degludec
Nationwide|Audit||||(6,949)||(6,949)|
|Nationwide
Audit Therapies|||Audit fund||(42)||(42)|
|Canagliflozin
audit|||||(20,497)||(20,497)|
|I ibre audit||||134,298|(101,134)||33,164|
|Testosterone
audit||||82,798|(36,114)||46,684|
|Semaglutide
audit||||60,997|(21,867)||39,130|
|Empagliflozin
audit|||||(20,497)||(20,497)|
|ABCD Research fund|||||(72,473)||(72,473)|
|COVID Diabetes
National
Omnipod
Audit
TOTAL FUNDS||Audit||109,800
387,893
516,790|(29,365)
~59945)
~391,270)
~476,086)|~10,653)|(29,365)
49 855
~3,377)
30,051|
##
##